FDA-approved profile

Imagio Breast Imaging System

Seno Medical Instruments, Inc. · Optoacoustic Imaging · FDA-approved (PMA)

Imagio combines ultrasound and optoacoustic imaging to evaluate palpable or non-palpable breast abnormalities in adults referred for diagnostic workup. Ultrasound can assign BI-RADS, and optoacoustic features can assist assessment of BI-RADS 3-5 masses based on vascularity and blood oxygen saturation.

Clinical role
Ultrasound and optoacoustic breast examination, BI-RADS support, and adjunctive mass assessment.
Images and patients
Optoacoustic Imaging · Breast
Key limitation
The system is adjunctive to diagnostic workup and is not a replacement for mammographic screening or definitive pathology. Use optoacoustic assessment only for labeled BI-RADS 3-5 masses and review the underlying ultrasound and clinical context.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyOptoacoustic Imaging · Breast
  • Workflow roleUltrasound and optoacoustic breast examination, BI-RADS support, and adjunctive mass assessment.
  • Required inputSupported adult breast ultrasound acquisitions and optoacoustic data from the Imagio system.
  • Output and human actionUltrasound images, optoacoustic vascularity and oxygen-saturation features, BI-RADS assistance, and reviewed breast findings.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Imagio combines ultrasound and optoacoustic imaging to evaluate palpable or non-palpable breast abnormalities in adults referred for diagnostic workup. Ultrasound can assign BI-RADS, and optoacoustic features can assist assessment of BI-RADS 3-5 masses based on vascularity and blood oxygen saturation.
  • Exact FDA submission
  • Checked 2026-09-03
Workflow role
Ultrasound and optoacoustic breast examination, BI-RADS support, and adjunctive mass assessment.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Supported adult breast ultrasound acquisitions and optoacoustic data from the Imagio system.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
Ultrasound images, optoacoustic vascularity and oxygen-saturation features, BI-RADS assistance, and reviewed breast findings.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Breast-imaging departments performing supported ultrasound and optoacoustic diagnostic workups.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified breast-imaging technologists and interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
The system is adjunctive to diagnostic workup and is not a replacement for mammographic screening or definitive pathology. Use optoacoustic assessment only for labeled BI-RADS 3-5 masses and review the underlying ultrasound and clinical context.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
The PMA approval describes ultrasound and optoacoustic modes, AI assistance for BI-RADS assessment, and the diagnostic-workup indication. Optoacoustic mode is not indicated for BI-RADS 1 or 2 findings, and the system is not a replacement for mammographic screening or definitive pathology; the approval statement is not a universal sensitivity or specificity claim.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The PMA approval describes ultrasound and optoacoustic modes, AI assistance for BI-RADS assessment, and the diagnostic-workup indication. Optoacoustic mode is not indicated for BI-RADS 1 or 2 findings, and the system is not a replacement for mammographic screening or definitive pathology; the approval statement is not a universal sensitivity or specificity claim.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

P200003 FDA performance package for Imagio Breast Imaging System

  • DesignFDA PMA review of analytical, clinical, usability, and optoacoustic breast-imaging evidence
  • PopulationAdults with palpable or non-palpable breast abnormalities referred for diagnostic workup after clinical presentation or prior imaging
  • Scopeexact submission
  • Tested versionImagio Breast Imaging System
  • IndependenceSponsor or vendor study

P200003

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

2 unlinked candidate evidence records are retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to P200003 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported adult breast ultrasound acquisitions and optoacoustic data from the Imagio system.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · P200003 FDA decision source

  2. Routing

    Source context, not route validation: Validate the acquisition console, data storage, image review, patient matching, report workflow, and any export or archive interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · P200003 FDA decision source

  3. AI processing

    Source context, not route validation: Installed Imagio breast-imaging system with the cleared ultrasound and optoacoustic modes.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · P200003 FDA decision source

  4. Returned objects

    Source context, not route validation: Ultrasound images, optoacoustic vascularity and oxygen-saturation features, BI-RADS assistance, and reviewed breast findings.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · P200003 FDA decision source

  5. Viewer/worklist/report

    Unresolved route: Ultrasound images, optoacoustic vascularity and oxygen-saturation features, BI-RADS assistance, and reviewed breast findings.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · P200003 FDA decision source

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed Imagio breast-imaging system with the cleared ultrasound and optoacoustic modes.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Validate the acquisition console, data storage, image review, patient matching, report workflow, and any export or archive interface.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Seno Medical's cybersecurity page states that Seno supports device cybersecurity through risk management and active vulnerability monitoring, and provides a Product Security Issue Report Form for coordinated vulnerability reports to cybersecurity@senomedical.com, with additional restricted security information for active customers.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Seno Medical generally and does not name the Imagio Breast Imaging System or any specific release; exact-release scope is not established.

Training
Only qualified breast-imaging technologists and interpreting physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The system is adjunctive to diagnostic workup and is not a replacement for mammographic screening or definitive pathology. Use optoacoustic assessment only for labeled BI-RADS 3-5 masses and review the underlying ultrasound and clinical context.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to P200003 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Validate the acquisition console, data storage, image review, patient matching, report workflow, and any export or archive interface.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. The capability is derived from the exact FDA workflow and still requires local acceptance testing.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The system is adjunctive to diagnostic workup and is not a replacement for mammographic screening or definitive pathology. Use optoacoustic assessment only for labeled BI-RADS 3-5 masses and review the underlying ultrasound and clinical context.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The system is adjunctive to diagnostic workup and is not a replacement for mammographic screening or definitive pathology. Use optoacoustic assessment only for labeled BI-RADS 3-5 masses and review the underlying ultrasound and clinical context.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. The capability is derived from the exact FDA workflow and still requires local acceptance testing.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
P200003
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Optoacoustic Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Clearance type
PMA
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-01-11
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-approved
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
3Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials were reviewed for identity, indication, users, workflow, limitations, and submitted performance. Current vendor material is labeled product-family context where it does not establish the exact release. PubMed and ClinicalTrials.gov results are retained as candidate evidence with version applicability pending; CMS reimbursement context and exact-identifier openFDA postmarket results were also checked. Pricing, final security architecture, contracted services, enabled options, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 0 PubMed and 3 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 2 history items

Source ledger

  1. P200003 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. IMAging With Opto-acoustics to downgradE BI-RADS claSsificaTion Relative tO Other Diagnostic Methodologies (MAESTRO)

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  8. The PIONEER-01 Study of the Imagio Breast Imaging System

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  9. CONFIDENCE Registry

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  10. Seno Medical: Cybersecurity

    Seno Medical Instruments, Inc. - Accessed 2026-10-27

    Scope: security

Research history

  1. P200003 FDA decision

    Regulatory record

    PMA

  2. Source-review record updated

    Research record

    human reviewed

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history